Mural Oncology plc (NASDAQ:MURA) CEO Sells $36,465.21 in Stock

Mural Oncology plc (NASDAQ:MURAGet Free Report) CEO Caroline Loew sold 12,531 shares of the business’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $2.91, for a total transaction of $36,465.21. Following the completion of the sale, the chief executive officer now owns 240,391 shares in the company, valued at approximately $699,537.81. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Mural Oncology Stock Up 1.3 %

Mural Oncology stock opened at $3.04 on Thursday. The stock has a 50-day simple moving average of $3.42 and a 200 day simple moving average of $4.24. Mural Oncology plc has a 12-month low of $2.88 and a 12-month high of $17.00.

Mural Oncology (NASDAQ:MURAGet Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($1.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.82. Sell-side analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on MURA. Rodman & Renshaw began coverage on shares of Mural Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $15.00 target price on the stock. Morgan Stanley began coverage on shares of Mural Oncology in a research note on Thursday, April 4th. They issued an “overweight” rating and a $13.00 target price on the stock.

Get Our Latest Stock Report on MURA

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mural Oncology stock. Harbor Capital Advisors Inc. acquired a new position in shares of Mural Oncology plc (NASDAQ:MURAFree Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 36,769 shares of the company’s stock, valued at approximately $115,000. Harbor Capital Advisors Inc. owned about 0.22% of Mural Oncology at the end of the most recent quarter. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Mural Oncology Company Profile

(Get Free Report)

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.

See Also

Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with's FREE daily email newsletter.